Helen M. Thackray - 01 Apr 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
Chief R&D Officer
Signature
/s/ Alane P. Barnes, by power of attorney
Issuer symbol
BCRX
Transactions as of
01 Apr 2022
Net transactions value
-$123,120
Form type
4
Filing time
04 Apr 2022, 16:32:37 UTC
Previous filing
16 Dec 2021
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Sale $123,120 -7,600 -5.3% $16.20 136,400 01 Apr 2022 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022.
F2 Shares sold to satisfy the reporting person's withholding obligations upon the vesting of restricted stock units granted in 2021.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $16.09 to $16.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.